Skip to main content

Welcome to the Fungal Forum

Scientific image of Cryptococcus

Welcome to the Fungal Forum

Disease information and news to help you stay one step ahead of invasive fungal infections (IFIs).

Two doctors reviewing notes on an iPad

WHY IS IT IMPORTANT TO SUSPECT IFIs?

IFIs are life-threatening conditions caused by yeasts or moulds with high mortality rates that range from 40-100% in patients who are immunocompromised, or have an underlying condition.1-6 Treatment can be challenging as a number of fungi responsible for these infections are resistant to many available antifungals, including azole and echinocandin options.7,8 The timely diagnosis of these serious infections is crucial, however the signs and symptoms are often non-specific and similar to those of bacterial or viral infections. Furthermore, access to modern diagnostic tools or biomarkers can be limited, delaying the initiation of an appropriate treatment.9,10

Time is of the essence in the fight against IFIs.

Microscopic photograph of fungus

HOW IS THE FUNGAL LANDSCAPE CHANGING?

Difficult-to-treat fungal pathogens are emerging worldwide, and have become more frequent than in previous years.7,8 Explore the changing trends and epidemiology across the world to help you manage a variety of IFIs.

Patient in bed with heart monitor

WHAT ARE THE SERIOUS MANIFESTATIONS OF IFIs?

IFIs can lead to a spectrum of other life-threatening conditions, such as sepsis or pneumonia.11-19 Learn about the most serious manifestations of IFIs, their epidemiology, prognosis, and risk factors.

Photo of clock face

HOW CAN YOU MANAGE IFIs PROMPLTY AND EFFECTIVELY?

Early suspicion of IFIs in your at-risk patients is key to improving treatment success.20-22 When you need to act quickly, know how to spot the signs and symptoms of IFIs so you can expedite treatment.
Three doctors reviewing notes

ARE DRUG-DRUG INTERACTIONS A CONCERN? CHOOSING THE RIGHT ANTIFUNGAL

Awareness of antifungal drug-drug interactions (DDIs) is important when treating patients on multiple medications, such as those in intensive care units (ICUs) or those with haematological malignancies or HIV/AIDs.23 Learn how to assess and manage DDI risk in your critically ill patients.
Doctor wearing hair net and surgical mask looking through window blind

HOW HAS THE CHALLENGE OF ANTIFUNGAL RESISTANCE EVOLVED?

Antifungal resistance can limit treatment options, with some species demonstrating resistance to multiple drug classes.24 Learn about the growing threat and the recommendations for tackling resistance in your area.

RECOMMENDED NEWS FOR ICU SPECIALISTS

References

  • Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
  • Logan C et al. Intensive Care Med. 2020;46(11):2001-2014.
  • Tomiyama T et al. Surg Case Rep. 2021;12;7(1):118.
  • Moorthy A et al. J Maxillofoc Oral Surg. 2021;1-8.
  • Iyer KR et al. Nat Rev Microbiol. 2021;8:1-13.
  • Lass-Flörl C and Cuenca-Estrella M. J Antimicrob Chemother. 2017;72(Suppl. 1):i5–11.
  • Arendrup MC. Clin Microbial Infect. 2014;20(Suppl. 6):42-44.
  • Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30(1):51-83.
  • Riwes MM and Wingard JR. Expert Rev Hematol. 2012;5(6):661-669.
  • Falci DR. Infect Dis Ther 2017;6(2):213-223.
  • Xie G et al. Crit Care. 2008;12(1):R5.
  • Bassetti M et al. Intensive Care Med. 2014;40:839-845.
  • Duggan S et al. Virulence. 2015;6(4):316-326.
  • Delaloye J and Calandra T. Virulence: 2014;5(1):161-169.
  • Góralska K et al. Infection. 2018;46:443-459.
  • Okike IO et al. Lancet Infect Dis. 2014;14(4):P301-P307.
  • Frare e Silva R. J Bras Pneumol. 2010;36(1):142-147.
  • Smith JA and Kauffman CA. Respirology. 2012;17:913-926.
  • Fernandez JF et al. Respir Care. 2013;58(5):e60-e63.
  • Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
  • Chatelon J et al. Adv Ther 2019;36(12):3308-3320.
  • Pagano L and Mayor S. Future Sci OA. 2018;4(6):FSO307.
  • Bartelli et al. Curr Fungal Infect Rep. 2010;4:103-110.
  • Perlin DS et al. Lancet Infect Dis. 2017;17(12):e383-e392.

Date of preparation: April 2022. Job code IHQ-AMB-0422.